AI Science Tracker

An AI breast-cancer screening system evaluated in two countries

Google DeepMind; Google Health, Cancer Research UK Imperial Centre, and Northwestern University · 1 Jan 2020 · medicine

Discovery

An AI breast-cancer screening system evaluated in two countries

Among 25,856 women in the UK and 3,097 in the US, the system reduced false positives by 5.7% (US) and 1.2% (UK), and false negatives by 9.4% and 2.7% in absolute terms compared with radiologists. Trained only on UK data, it also outperformed specialists on US data. Retrospective evaluation (Nature): prospective studies are needed, and clinical deployment is unclear.

Technology: Neural network for mammograms

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Retrospective evaluation on UK (25,856 women) and US (3,097 women) screening mammograms, compared with individual radiologists' decisions; a reader study and a simulated double-reading workflow were also run.
  • Still unknown: The authors state prospective studies are required and that how to deploy the system clinically is not yet determined; the US data were enriched; the second-reader scenario was only simulated.
  • AI role: Predicted from screening mammograms alone whether a biopsy would later show cancer.

Evidence sources: https://deepmind.google/blog/international-evaluation-of-an-ai-system-for-breast-cancer-screening/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-019-1799-6&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 3668 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.